Trends in congenital cytomegalovirus: A review of current screening methods and prevention strategies

Francine H. Tvrdy, Troy Johnson, Jeff Hoffman, Julie A. Honaker, Stephen J. Boney

Research output: Contribution to journalReview article

Abstract

Cytomegalovirus (CMV) is one of the leading causes of congenital sensorineural hearing loss. Currently, 40,000 infants in the United States are infected annually with CMV, and of these 40,000 infants, upward of 6000 infants will develop sensorineural hearing loss. Most of these infants will go undetected for congenital hearing loss by a newborn screening program, due to having late-onset or progressive hearing loss. An efficient CMV screening program of newborns will help to identify those infected and at risk for developing sensorineural hearing loss. Also, it will allow close monitoring of these infants for maximum speech and language development. Reliable methods are needed for an effective CMV screening program. Because the dried blood spot (DBS) sample is routinely collected at birth for metabolic screenings, there is growing interest to adapt this as the universal screening method. However, sensitivity of the DBS in detecting CMV has varied, and recent evidence has shown it less reliable than urine or saliva analysis. Further research is needed to develop the most efficient, reliable, and cost-effective programs. Models such as the Quebec metabolic screening program may ensure earlier identification of CMV. We are closer to a means of prophylactic prevention with a CMV vaccine; however, increased patient education of CMV prevention by health care professionals, including audiologists, is the current best practice for reducing the incidence of CMV infection.

Original languageEnglish (US)
Pages (from-to)321-331
Number of pages11
JournalSeminars in Hearing
Volume32
Issue number4
DOIs
StatePublished - Nov 2 2011

Fingerprint

Cytomegalovirus
Sensorineural Hearing Loss
Hearing Loss
Cytomegalovirus Vaccines
Newborn Infant
Language Development
Quebec
Cytomegalovirus Infections
Patient Education
Saliva
Practice Guidelines
Urine
Parturition
Delivery of Health Care
Costs and Cost Analysis
Incidence
Research

Keywords

  • Cytomegalovirus
  • congenital sensorineural hearing loss
  • dried blood spot
  • prevention

ASJC Scopus subject areas

  • Speech and Hearing

Cite this

Trends in congenital cytomegalovirus : A review of current screening methods and prevention strategies. / Tvrdy, Francine H.; Johnson, Troy; Hoffman, Jeff; Honaker, Julie A.; Boney, Stephen J.

In: Seminars in Hearing, Vol. 32, No. 4, 02.11.2011, p. 321-331.

Research output: Contribution to journalReview article

Tvrdy, Francine H. ; Johnson, Troy ; Hoffman, Jeff ; Honaker, Julie A. ; Boney, Stephen J. / Trends in congenital cytomegalovirus : A review of current screening methods and prevention strategies. In: Seminars in Hearing. 2011 ; Vol. 32, No. 4. pp. 321-331.
@article{b95376c0ba7c48469fe21c7750ab2f56,
title = "Trends in congenital cytomegalovirus: A review of current screening methods and prevention strategies",
abstract = "Cytomegalovirus (CMV) is one of the leading causes of congenital sensorineural hearing loss. Currently, 40,000 infants in the United States are infected annually with CMV, and of these 40,000 infants, upward of 6000 infants will develop sensorineural hearing loss. Most of these infants will go undetected for congenital hearing loss by a newborn screening program, due to having late-onset or progressive hearing loss. An efficient CMV screening program of newborns will help to identify those infected and at risk for developing sensorineural hearing loss. Also, it will allow close monitoring of these infants for maximum speech and language development. Reliable methods are needed for an effective CMV screening program. Because the dried blood spot (DBS) sample is routinely collected at birth for metabolic screenings, there is growing interest to adapt this as the universal screening method. However, sensitivity of the DBS in detecting CMV has varied, and recent evidence has shown it less reliable than urine or saliva analysis. Further research is needed to develop the most efficient, reliable, and cost-effective programs. Models such as the Quebec metabolic screening program may ensure earlier identification of CMV. We are closer to a means of prophylactic prevention with a CMV vaccine; however, increased patient education of CMV prevention by health care professionals, including audiologists, is the current best practice for reducing the incidence of CMV infection.",
keywords = "Cytomegalovirus, congenital sensorineural hearing loss, dried blood spot, prevention",
author = "Tvrdy, {Francine H.} and Troy Johnson and Jeff Hoffman and Honaker, {Julie A.} and Boney, {Stephen J.}",
year = "2011",
month = "11",
day = "2",
doi = "10.1055/s-0031-1291936",
language = "English (US)",
volume = "32",
pages = "321--331",
journal = "Seminars in Hearing",
issn = "0734-0451",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Trends in congenital cytomegalovirus

T2 - A review of current screening methods and prevention strategies

AU - Tvrdy, Francine H.

AU - Johnson, Troy

AU - Hoffman, Jeff

AU - Honaker, Julie A.

AU - Boney, Stephen J.

PY - 2011/11/2

Y1 - 2011/11/2

N2 - Cytomegalovirus (CMV) is one of the leading causes of congenital sensorineural hearing loss. Currently, 40,000 infants in the United States are infected annually with CMV, and of these 40,000 infants, upward of 6000 infants will develop sensorineural hearing loss. Most of these infants will go undetected for congenital hearing loss by a newborn screening program, due to having late-onset or progressive hearing loss. An efficient CMV screening program of newborns will help to identify those infected and at risk for developing sensorineural hearing loss. Also, it will allow close monitoring of these infants for maximum speech and language development. Reliable methods are needed for an effective CMV screening program. Because the dried blood spot (DBS) sample is routinely collected at birth for metabolic screenings, there is growing interest to adapt this as the universal screening method. However, sensitivity of the DBS in detecting CMV has varied, and recent evidence has shown it less reliable than urine or saliva analysis. Further research is needed to develop the most efficient, reliable, and cost-effective programs. Models such as the Quebec metabolic screening program may ensure earlier identification of CMV. We are closer to a means of prophylactic prevention with a CMV vaccine; however, increased patient education of CMV prevention by health care professionals, including audiologists, is the current best practice for reducing the incidence of CMV infection.

AB - Cytomegalovirus (CMV) is one of the leading causes of congenital sensorineural hearing loss. Currently, 40,000 infants in the United States are infected annually with CMV, and of these 40,000 infants, upward of 6000 infants will develop sensorineural hearing loss. Most of these infants will go undetected for congenital hearing loss by a newborn screening program, due to having late-onset or progressive hearing loss. An efficient CMV screening program of newborns will help to identify those infected and at risk for developing sensorineural hearing loss. Also, it will allow close monitoring of these infants for maximum speech and language development. Reliable methods are needed for an effective CMV screening program. Because the dried blood spot (DBS) sample is routinely collected at birth for metabolic screenings, there is growing interest to adapt this as the universal screening method. However, sensitivity of the DBS in detecting CMV has varied, and recent evidence has shown it less reliable than urine or saliva analysis. Further research is needed to develop the most efficient, reliable, and cost-effective programs. Models such as the Quebec metabolic screening program may ensure earlier identification of CMV. We are closer to a means of prophylactic prevention with a CMV vaccine; however, increased patient education of CMV prevention by health care professionals, including audiologists, is the current best practice for reducing the incidence of CMV infection.

KW - Cytomegalovirus

KW - congenital sensorineural hearing loss

KW - dried blood spot

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=80055062005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055062005&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1291936

DO - 10.1055/s-0031-1291936

M3 - Review article

AN - SCOPUS:80055062005

VL - 32

SP - 321

EP - 331

JO - Seminars in Hearing

JF - Seminars in Hearing

SN - 0734-0451

IS - 4

ER -